Therefore, the identification of isoform-selective compounds and inhibitors that target specific domains of HSP90, such as the CTD, can be an effective tool for understanding the role played by each isoform in cancer and potentially reduce toxicities associated with pan-inhibition. The gene discussed is HSP90AB1; the disease is cancer.